ArticleThe Journal of experimental medicine2006
Giving blood: a new role for CD40 in tumorigenesis.
Article in The Journal of experimental medicine, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 38 citations in OpenAlex.
- Exosomal CD40, CD25, and Serum CA19-9 as Combinatory Novel Liquid Biopsy Biomarker for the Diagnosis and Prognosis of Patients with Pancreatic Ductal Adenocarcinoma.International journal of molecular sciences · 2025Article
- Harnessing the potential of CD40 agonism in cancer therapy.Cytokine & growth factor reviews · 2024Review
- Rapamycin as a Potential Alternative Drug for Squamous Cell Gingiva Carcinoma (Ca9-22): A Focus on Cell Cycle, Apoptosis and Autophagy Genetic Profile.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Impact of CD40 gene polymorphisms on the risk of cervical squamous cell carcinoma: a case-control study.BMC cancer · 2023Article
- CD40 Cross-Linking Induces Migration of Renal Tumor Cell through Nuclear Factor of Activated T Cells (NFAT) Activation.International journal of molecular sciences · 2021Article
- A fully human IgG1 anti-PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses.Clinical & translational immunology · 2016Article
- Anti-CD40-induced inflammatory E-cadherin+ dendritic cells enhance T cell responses and antitumour immunity in murine Lewis lung carcinoma.Journal of experimental & clinical cancer research : CR · 2015Article
- Manipulated microenvironment in human papilloma virus-infected epithelial cells: is the CD40-CD154 pathway beneficial for host or virus?The Journal of investigative dermatology · 2014Article
- Multifunctional CD40L: pro- and anti-neoplastic activity.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Clinical significance of elevated serum soluble CD40 ligand levels as a diagnostic and prognostic tumor marker for pancreatic ductal adenocarcinoma.Journal of translational medicine · 2014Article
- CD40 immunotherapy for pancreatic cancer.Cancer immunology, immunotherapy : CII · 2013Review
- Agonistic CD40 antibodies and cancer therapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013Article
- Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role.Blood · 2012Article
- TRAF6 inhibits proangiogenic signals in endothelial cells and regulates the expression of vascular endothelial growth factor.Biochemical and biophysical research communications · 2012Article
- Inhibition of CD40-CD154 costimulatory pathway by a cyclic peptide targeting CD154.Journal of molecular medicine (Berlin, Germany) · 2009Article
- CD40-induced signaling in human endothelial cells results in mTORC2- and Akt-dependent expression of vascular endothelial growth factor in vitro and in vivo.Journal of immunology (Baltimore, Md. : 1950) · 2008Article
- Anti-CD40 agonist antibodies: preclinical and clinical experience.Update on cancer therapeutics · 2007Article
- Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma.OncoimmunologyArticle
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CD40 was initially identified as a receptor expressed by B cells that is crucial for inducing an effective adaptive immune response. CD40 was subsequently shown to be expressed by endothelial cells and to promote angiogenesis. New data now show that in tumor-prone transgenic mice, CD40-mediated neovascularization is essential for early stage tumorigenicity. This suggests, at least in this mouse model, that CD40 has an important role in the angiogenic process that is coupled to carcinogenesis, a finding that could lead to novel therapeutic opportunities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.